



In re Application of: Wang et al.
 Application No. 09/529,206
 Filed: June 13, 2000
 For: HUMAN CANCER ANTIGEN NY ESO-1/CAG-3 AND GENE ENCODING THE SAME

Mail Stop Amendment
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a response to an office action in the subject application.

Small entity status is claimed for this application under 37 CFR 1.27.

Petition for an extension of time for the period noted below, as well as for any additional period necessary to render the present submission timely. Please charge Deposit Account No. 12-1216 for the appropriate petition fee.

Other: Fed. Reg., Vol. 66, No. 4, p.1101,(Jan. 5, 2001); Falk et al. , Immunogenetics 40:238-241 (1994); Missale et al. ,J. Exp. Med. 177: 751-762 (1993).

Please charge Deposit Account No. 12-1216 in the total amount indicated below. A duplicate copy of this transmittal sheet is enclosed herewith.

					SMALL ENTITY	OTHER THAN A SMALL ENTITY	
TIME EXTENSION PETITION FEE		none			\$ 0.00	\$ 0.00	
	subtract time extension fee previously paid	none			(\$ 0.00)	(\$ 0.00)	
CLAIM FEE	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	EXTRA CLAIMS PRESENT	RATE	ADD'L CLAIM FEE	RATE
TOTAL	45	MINUS	103	= 0	x 9=	\$	x 18= \$ 0.00
INDEPENDENT	3	MINUS	3	= 0	x 43=	\$	x 86= \$ 0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE CLAIM					+ 145=	\$	+ 290= \$ 0.00
TOTAL AMOUNT TO BE CHARGED TO DEPOSIT ACCOUNT					TOTAL	\$	TOTAL

The Commissioner is hereby authorized to charge any deficiencies in the following fees associated with this communication or credit any overpayment to Deposit Account No. 12-1216.

Any filing fees under 37 CFR 1.16 for the presentation of extra claims.


Any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,
 LEYDIG, VOIT & MAYER, LTD.

By

 David J. Schodin, Reg. No. 41,294

Leydig, Voit & Mayer, Ltd.
 Two Prudential Plaza, Suite 4900
 180 North Stetson Avenue
 Chicago, Illinois 60601-6780
 (312) 616-5600 (telephone)
 (312) 616-5700 (facsimile)

1642
JFW

PATENT
Attorney Docket No. 218791
Client Reference No. E-265-1997/0-US-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wang et al.

Application No. 09/529,206

Art Unit: 1642

Examiner: David J. Blanchard

Filed: June 13, 2000

For: HUMAN CANCER ANTIGEN NY
ESO-1/CAG-3 AND GENE
ENCODING THE SAME

RESPONSE TO OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated July 2, 2004, please consider the following remarks.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this Response to Office Action and all accompanying documents are, on the date indicated below, being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Examiner L. R. Helms, Art Unit 1642, Facsimile Number

Name (Print/Type)	<i>David J. Blanchard</i>		
Signature	<i>David J. Blanchard</i>	Date	September 22, 2004